Patients with nonalcoholic fatty liver disease are reported to have greater COVID-19 severity than those without nonalcoholic fatty liver disease. The aspartate aminotransferase to platelet ratio index consists of two parameters, aspartate aminotransferase and platelet count, and is much simpler than other liver fibrosis scores. The aspartate aminotransferase to platelet ratio index was independently associated with COVID-19 severity and hospitalization duration for COVID-19 in patients with nonalcoholic fatty liver disease.

A total of 71 254 participants from 13 health centers in Japan were analyzed, with an overall prevalence of NAFLD of 25.8%. A total of 14% of NAFLD patients had diabetes, 31% had hypertension, and 48% had dyslipidemia. The estimated prevalence of NAFLD with advanced fibrosis was 1%–2%.

Among the 405 patients who received pulse steroid therapy, five patients (1.2%) developed drug-induced autoimmune-like hepatitis (DI-ALH). Prednisolone was effective for DI-ALH due to pulse steroid therapy and could be safely withdrawn once remission was achieved.

Our study confirmed that the correlation between the wedged hepatic venous pressure (WHVP) and portal venous pressure groups and between the hepatic venous pressure gradient (HVPG) and portal pressure gradient groups was better in both triphasic shunting and portal vein visualization by innovative angiography, with the best agreement in the portal vein visualization group. Hepatic vein collateral branches were an important factor in underestimating WHVP and HVPG; the earlier the appearance of collateral branches, the more pronounced the underestimation. The absence of hepatic vein collateral veins is a crucial factor in the overestimation of the WHVP and HVPG.

PVT was diminished under anticoagulation, along with improved liver function and reduced risks for cirrhosis-related complications. The incidence of bleeding events was not increased by the treatment. As a consequence, mortality was reduced in PVT patients by anticoagulation therapy.

We conducted an optimal sequence kernel association test using exome data of 15 Japanese patients with non-syndromic type III biliary atresia and 509 control individuals. The results indicate that rare damaging variants in MFHAS1 may constitute a risk factor for non-syndromic biliary atresia; however, the overall contribution of monogenic variants to the disease predisposition is small.